Nature Reviews Rheumatology - Table of Contents alert Volume 12 Issue 5

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
May 2016 Volume 12 Number 5
Impact Factor 9.845 *	In this issue Research Highlights News and Views Reviews Also this month  Featured article: Adipokines in bone disease Elena Neumann, Susann Junker, Georg Schett, Klaus Frommer & Ulf Müller-Ladner
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
< Call for Cover Images Wanted: eye-catching images to feature on the 2017 covers of the clinical Nature Reviews titles. Submit your image for the opportunity for it to appear on the cover for 2017! PLUS we'll send the chosen author a print of the cover as a thank you.  Details of how to submit here
RESEARCH HIGHLIGHTS Top Rheumatoid arthritis: Sclerostin: a novel role in TNF arthritis? Published online: 04 April 2016 p251 | doi:10.1038/nrrheum.2016.51 PDF Crystal arthritis: Arhalofenate safely prevents gout flare Published online: 07 April 2016 p252 | doi:10.1038/nrrheum.2016.53 PDF Systemic lupus erythematosus: Compromised pDC-BREG cell crosstalk Published online: 24 March 2016 p253 | doi:10.1038/nrrheum.2016.43 PDF Genetics: Novel insights from large cross-disease study Published online: 04 April 2016 p253 | doi:10.1038/nrrheum.2016.50 PDF Rheumatoid arthritis: Metabolic interventions repair CD4+ T cells in RA Published online: 15 April 2016 p254 | doi:10.1038/nrrheum.2016.54 PDF IN BRIEF Vasculitis syndromes: Efficacy of tocilizumab for GCA in RCT | Rheumatoid arthritis: Antidrug antibodies crossreact with biosimilars | Connective tissue diseases: Steroidal nano-drug suppresses murine lupus | Osteoarthritis: Vitamin D not effective for knee OA | Rheumatoid arthritis: Chronic underdiagnosis of CVD in patients with RA | Therapy: Methotrexate dosing can be optimized | Spondyloarthropathies: Anti-TNF drugs should be tapered, not halted | Prevention: Time to re-evaluate herpes zoster vaccination? PDF Rheumat0logy EVENT National Pediatric Rheumatology Conference 2016 28.08.16 BANGALORE, Inida More science events from
NEWS AND VIEWS		Top
Therapy: The NICE position on indications for biologics and biosimilars Morton Scheinberg & Juan J. Gomez-Reino Published online: 15 April 2016 p255 | doi:10.1038/nrrheum.2016.56 New guidance issued by NICE in the UK addresses issues of when and for whom to introduce biologic drugs, including biosimilars, in the treatment of rheumatoid arthritis. Could differences between these recommendations and those of national societies have implications for patient care? Full Text | PDF
Autoinflammation: When is familial Mediterranean fever 'severe'? Helen J. Lachmann & Paul A. Brogan Published online: 25 April 2016 p256 | doi:10.1038/nrrheum.2016.55 Familial Mediterranean fever is a rare disorder but is usually easy to manage using colchicine. The publication of a severity score could serve as a useful reminder to rheumatologists about this disease and the difficulties in assessing its severity. Full Text | PDF
REVIEWS		Top
Macrophage activation syndrome in the era of biologic therapy Alexei A. Grom, AnnaCarin Horne & Fabrizio De Benedetti Published online: 24 March 2016 p259 | doi:10.1038/nrrheum.2015.179 Macrophage activation syndrome (MAS) is a potentially fatal complication of rheumatic disease, most notably systemic juvenile idiopathic arthritis. Findings from studies in animal models and from clinical observations, particularly in relation to the effects of anticytokine biologic therapies, have led to new concepts of the pathophysiology of this phenomenon. Abstract | Full Text | PDF | Supplementary information
Metabolomics in rheumatic diseases: desperately seeking biomarkers Monica Guma, Stefano Tiziani & Gary S. Firestein Published online: 03 March 2016 p269 | doi:10.1038/nrrheum.2016.1 In the setting of inflammatory diseases, metabolic profiling has potential applications in diagnosis, monitoring and defining disease pathogenesis. This Review focuses on metabolomic studies in rheumatic diseases, including discussion of state-of-the-art technologies, recent insights into disease mechanisms and treatment targets, and the feasibility of metabolomics for biomarker discovery. Abstract | Full Text | PDF | Supplementary information
New evidence on the management of spondyloarthritis Joachim Sieper & Denis Poddubnyy Published online: 07 April 2016 p282 | doi:10.1038/nrrheum.2016.42 The availability of new agents to treat patients with spondyloarthritis and the results of clinical trials published in the past few years provide new perspectives on the optimal management of these patients. In this article, Sieper and Poddubnyy review the current options for management of axial and peripheral spondyloarthritis on the basis of the latest evidence. Abstract | Full Text | PDF
Adipokines in bone disease Elena Neumann, Susann Junker, Georg Schett, Klaus Frommer & Ulf Müller-Ladner Published online: 15 April 2016 p296 | doi:10.1038/nrrheum.2016.49 The influence of adipokines on the pathogenesis and progression of rheumatic diseases is increasingly appreciated. In particular, these factors have complex roles not only in inflammation, but in tissue remodelling. This Review focuses on the effects of distinct adipokines on bone cells and bone remodelling, and discusses whether these mechanisms could be targeted therapeutically. Abstract | Full Text | PDF
New perspectives on femoroacetabular impingement syndrome Moin Khan, Asheesh Bedi, Freddie Fu, Jon Karlsson, Olufemi R. Ayeni & Mohit Bhandari Published online: 10 March 2016 p303 | doi:10.1038/nrrheum.2016.17 In patients with symptomatic femoroacetabular impingement (FAI), early correction of the anatomical dysfunction could delay or prevent the development of hip osteoarthritis. Accordingly, the past 5 years has seen a huge increase in minimally invasive, arthroscopic correction of FAI and a correspondingly rapid rise in FAI-related research. Khan and colleagues discuss the clinical evidence and emerging concepts of the pathophysiology, biomechanics and management of FAI. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2014. Nature Reviews Rheumatology was previously published as Nature Clinical Practice Rheumatology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.